Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies.
Bone Marrow Transplant
; 17 Suppl 3: S11-3, 1996 May.
Article
em En
| MEDLINE
| ID: mdl-8769692
ABSTRACT
Six-hundred patients were recruited between 1986 and 1991 for studies of the treatment of Ph positive chronic myeloid leukemia (CML) with interferon-alpha (IFN-alpha). The median survival of the patients who were assigned to treatment with IFN-alpha was 6 years or longer than 6 years, and was more than the survival of the patients who were assigned to conventional chemotherapy. Survival prolongation was significantly related with the achievement of a cytogenetic response. IFN-alpha treatment was not harmful for subsequent allogeneic or autologous bone marrow transplantation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Interferon-alfa
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
País como assunto:
Europa
Idioma:
En
Ano de publicação:
1996
Tipo de documento:
Article